Division of Endocrinology, Department of Medicine, University of Texas Health San Antonio (UTHSA), San Antonio, Texas.
Division of Hematology and Medical Oncology, Department of Medicine, UTHSA, San Antonio, Texas.
J Clin Endocrinol Metab. 2021 Jan 1;106(1):e350-e364. doi: 10.1210/clinem/dgaa741.
This work aimed to evaluate genotype-phenotype associations in individuals carrying germline variants of transmembrane protein 127 gene (TMEM127), a poorly known gene that confers susceptibility to pheochromocytoma (PHEO) and paraganglioma (PGL).
Data were collected from a registry of probands with TMEM127 variants, published reports, and public databases.
Clinical, genetic, and functional associations were determined.
The cohort comprised 110 index patients (111 variants) with a mean age of 45 years (range, 21-84 years). Females were predominant (76 vs 34, P < .001). Most patients had PHEO (n = 94; 85.5%), although PGL (n = 10; 9%) and renal cell carcinoma (RCC, n = 6; 5.4%) were also detected, either alone or in combination with PHEO. One-third of the cases had multiple tumors, and known family history was reported in 15.4%. Metastatic PHEO/PGL was rare (2.8%). Epinephrine alone, or combined with norepinephrine, accounted for 82% of the catecholamine profiles of PHEO/PGLs. Most variants (n = 63) occurred only once and 13 were recurrent (2-12 times). Although nontruncating variants were less frequent than truncating changes overall, they were predominant in non-PHEO clinical presentations (36% PHEO-only vs 69% other, P < .001) and clustered disproportionately within transmembrane regions (P < .01), underscoring the relevance of these domains for TMEM127 function. Integration of clinical and previous experimental data supported classification of variants into 4 groups based on mutation type, localization, and predicted disruption.
Patients with TMEM127 variants often resemble sporadic nonmetastatic PHEOs. PGL and RCC may also co-occur, although their causal link requires further evaluation. We propose a new classification to predict variant pathogenicity and assist with carrier surveillance.
本研究旨在评估跨膜蛋白 127 基因(TMEM127)种系变异个体的基因型-表型相关性,该基因变异与嗜铬细胞瘤(PHEO)和副神经节瘤(PGL)易感性相关,但目前对其了解甚少。
从携带 TMEM127 变异的先证者登记处、已发表的报告和公共数据库中收集数据。
确定了临床、遗传和功能相关性。
该队列包括 110 名指数患者(111 种变异),平均年龄 45 岁(范围 21-84 岁)。女性居多(76 例比 34 例,P<.001)。大多数患者为 PHEO(n=94;85.5%),但也检测到 10 例 PGL(9%)和 6 例肾细胞癌(RCC,5.4%),或单独或与 PHEO 联合存在。三分之一的病例有多个肿瘤,15.4%的病例有家族史。转移性 PHEO/PGL 罕见(2.8%)。仅肾上腺素或与去甲肾上腺素联合占 PHEO/PGL 儿茶酚胺谱的 82%。大多数变异(n=63)仅出现一次,13 次为重复(2-12 次)。尽管非截断变异总体上比截断变化少见,但在非 PHEO 临床表现中更为常见(仅 PHEO 中为 36%,其他为 69%,P<.001),并且不成比例地集中在跨膜区域(P<.01),这突显了这些区域对 TMEM127 功能的重要性。整合临床和以前的实验数据支持根据突变类型、定位和预测的破坏将变异分类为 4 组。
携带 TMEM127 变异的患者常类似于散发性非转移性 PHEO。PGL 和 RCC 也可能同时发生,但其因果关系需要进一步评估。我们提出了一种新的分类方法来预测变异的致病性,并有助于携带者监测。